Filing Details
- Accession Number:
- 0001493152-25-010435
- Form Type:
- 13D Filing
- Publication Date:
- 2025-03-13 20:00:00
- Filed By:
- Choo Chee Kong
- Company:
- Cytomed Therapeutics Ltd
- Filing Date:
- 2025-03-14
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Choo Chee Kong | 598,015 | 3,773,291 | 598,015 | 3,773,291 | 2,673,325 | 23.17% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
|
CytoMed Therapeutics Ltd (Name of Issuer) |
Ordinary Shares (Title of Class of Securities) |
Y1R80M106 (CUSIP Number) |
Choo Chee Kong #08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE Singapore, U0, 149544 65 6250 7738 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
02/20/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | Y1R80M106 |
| 1 |
Name of reporting person
Choo Chee Kong | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
SINGAPORE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
2,673,325.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
23.17 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Ordinary Shares |
| (b) | Name of Issuer:
CytoMed Therapeutics Ltd |
| (c) | Address of Issuer's Principal Executive Offices:
#08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE, Singapore,
SINGAPORE
, 149544. |
| Item 2. | Identity and Background |
| (a) | Choo Chee Kong |
| (b) | 1 Commonwealth Lane #08-22, Singapore 149544 |
| (c) | The Reporting Person is the Chairman of the Board and Director of the Issuer. The address of the Issuer is 1 Commonwealth Lane #08-22, Singapore 149544 |
| (d) | No |
| (e) | No |
| (f) | Singapore |
| Item 3. | Source and Amount of Funds or Other Consideration |
PF; Mr. Choo Chee Kong has acquired all of the ordinary shares, no par value, of CytoMed Therapeutics Limited (the "Issuer") (the "Ordinary Shares") beneficially owned by him (1) in exchange for capital contributions to the Issuer or (2) through public purchases on the open market with his personal funds. | |
| Item 4. | Purpose of Transaction |
Mr. Choo Chee Kong has acquired all of the Ordinary Shares beneficially owned by him (1) in exchange for capital contributions to the Issuer or (2) through public purchases on the open market with his personal funds for investment purposes. The Reporting Person serves as Chairman of the Issuer and is a member of the board of directors of the Issuer and, as a result, may be asked to vote on or discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others. Except as may be set forth herein, the Reporting Person has no current intention, plan or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D. | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows:
the Reporting Person beneficially owns 2,673,325 Ordinary Shares, representing 23.17% of the Issuer's outstanding shares as of the date hereof.
This includes: (1) 2,075,310 Ordinary Shares held indirectly through Glorious Finance Limited ("Glorious Finance"), in which Mr. Choo Chee Kong owns a 55% stake. As such, he is deemed to beneficially own 55% of the 3,773,291 shares held by Glorious Finance, while disclaiming ownership of the remainder. These shares were issued in exchange for capital contributions; (2) 410,515 Ordinary Shares held by EP Capital Inc. ("EP Capital"), which Mr. Choo Chee Kong is deemed to beneficially own. These shares were issued in exchange for capital contributions; and (3) 187,500 Ordinary Shares held directly by Mr. Choo Chee Kong, acquired with personal funds. The calculation is based on 11,540,000 Ordinary Shares outstanding as of the date hereof. |
| (b) | Please refer to Items 7-13 of the Cover Page. The Reporting Person has sole voting and dispositive power over 598,015 Ordinary Shares, and shared voting and dispositive power over 3,773,291 Ordinary Shares. |
| (c) | On February 20, 2025, Mr. Choo Chee Kong transferred 715,000 Ordinary Shares held by Glorious Finance Limited to 28 Consultants Limited as a gift. |
| (d) | None |
| (e) | N/A |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
The Reporting Person and the remaining shareholders of EP Capital may be deemed to be acting as a "group" under Section 13(d)(3) as they share voting and dispositive power over the 3,773,291 Ordinary Shares of the Issuer. However, there is no formal agreement governing their voting or investment decisions.
Except as set forth herein, the Reporting Person has no contracts, arrangements, understandings, or relationships with respect to the Issuer's securities requiring disclosure under this Item 6.
(20,000-character limit, line endings allowed, no formatting permitted) | |
| Item 7. | Material to be Filed as Exhibits. |
Except as set forth herein, there are no material agreements, contracts, arrangements, or understandings that require filing as exhibits under this Item 7. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|